Delivery Order SPE2DB20D1109-SPE2DB25FP55U
- Not listed
- The Defense Logistics Agency awarded a $4,171.54 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a $5,591.47 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This non-competitive delivery order represents a firm fixed-price contract with an ultimate completion date of August 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 mL syringes on June 18, 2025, with an ultimate completion date of June 20, 2025. This firm fixed-price, non-set-aside contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for $1,709.46 to supply Dupixent 200 mg/1.14 ml syringes. The contract, awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $17,094.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $26,943.08 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The pharmaceutical will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $7,437.53 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Dupixent 300 mg/2 ml syringes. This non-competitive, competitively awarded delivery order is scheduled for completion by September 3, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle...
- The Defense Logistics Agency awarded a $1,709.46 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 200 mg/1.14 ml syringes, with an ultimate completion date of July 28, 2025. This is a firm fixed price, non-set-aside contract, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $47,704.56 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP55UDelivery Order
The Defense Logistics Agency awarded a $1,709.46 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. The contract, which is a non-set-aside competitive award with firm fixed pricing, is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle valued through December 2026 that enables the company to distribute a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains through competitive delivery orders with firm fixed pricing. This award for Dupixent, a biologic treatment for atopic dermatitis and other inflammatory conditions, reflects the company's role in supporting military and federal healthcare supply chains with specialized pharmaceutical products.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/11/25 |